Posts in Category: People

Scott Rocklage, Founding Partner 5AM Venture

Expansion Therapeutics is an organization that deals with RNA illnesses. The company develops medicines that battle illnesses brought about by RNA. The company concerns itself with illnesses that are hereditary. Moreover, these genetical disorders are not responsive to existing medical interventions. These diseases have defective genes that cause respiratory, muscles and nervous system not to function well. Currently, Expansion therapeutics is raising funds to fight these heritable disorders. Particularly, the company is trying to battle with myotonic dystrophy type 1. Myotonic dystrophy 1 is also known as DM1. This disorder leads to muscle failure in adults.

Expansion therapeutics has set aside extra 55.3 million dollars for the fight of this specific disorder, DM1. Some ventures have come together with Expansion therapeutics to raise these funds. For instance, 5AM Venture, Sanofi ventures, and many more have teamed up with Expansion Therapeutics in the fight against DM1. Expansion therapeutics relies on science to produce medications that treat illnesses caused by RNA.

Scott Rocklage joined 5AM Ventures in 2013 as a venture partner. In 2014, Scott became the Managing Partner of the company. Currently, Scott is the founding partner of the company. Scott is a veteran of over 30 years in the healthcare field. With his tactical leadership responsibilities, he led 3 new U.S drug applications to get FDA approval. Previously, Dr. Rocklage has been the Chairman of the Board of Relypsa and Novira. Today, he is the chairman of board members of Kibestral, Rennovial, and Cidara.

Scott Rocklage went to the University of California where he received bachelor’s degree in chemistry. Later, he received his Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Scott works with physicians, scientists as well business executives as they help each other to create medical solutions that do not currently exist. As an investor, Dr. Rocklage has many patents in the U.S. In addition to this, he has several publications that are peer reviewed. Moreover, Dr. Moreover, Dr. Rocklage has served as CEO and president of Nycomed Salutar and Cubist Pharmaceuticals. Under the Dr. Scott Rocklage’s leadership, there are hopes that the company will come up with solutions to these RNA sicknesses that currently still don’t have cures. Learn more:

Scott Rocklage’s Advancements as a Passionate Scientist

Scott Rocklage has had a varied professional life in healthcare management, business and the life sciences for over 20 years. Mr. Rocklage says no two days follow a typical schedule. He credits his effectiveness to being well-organized in terms of time management, calendaring and prioritizing matters of importance.


Scott Rocklage received his B.S. degree in Chemistry from the University of California, Berkley. His Ph.D is from the Massachusetts Institute of Technology in Chemistry. In 2003, Mr. Rocklage became a venture partner with 5AM Ventures, and was promoted to managing partner one year later.


The company, 5AM Ventures, is a life sciences-based company. It works with other entities that are in early development or formation, and, that in part is the reason for the name of the company, 5AM Ventures.


Scott Rocklage has an active involvement in healthcare management outside 5AM Ventures. He has served in executive capacity with Nycomed Salutar and Nycomed Interventional. Moreover, he has held board of director memberships with the Whitehead Institute, Achaogen and Semprus. Presently, he works out of the Boston, Massachusetts office of 5AM Ventures. Mr. Rocklage has several patents as inventor or co-inventor, has been featured in 100 peer-reviewed publications, and was instrumental in leading the way toward FDA approval of three treatment protocols. These are Omniscan, Cubicin, and Teslascan. Mr. Rocklage has a high degree of interest in the steady growth to target mutations that will result in new forms of cancer treatment. He enjoys helping entrepreneurs, physicians and scientists shape their ideas into real possibilities that could find application in the marketplace. Learn more: